Skip to content

DBV Technologies DBVT Earnings yield

Earnings yield at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-24.9%-110pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-25.7%-6.8pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-13.4%-1.2pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-7.7%-3.7pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-4.6%-1.8pp
Alumis Inc. logo
Alumis Inc.ALMS
-8.5%-4.1pp

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$948.17M+269%
Enterprise value$725.07M+188%
P/S163.9×+91.4×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Calculated from DBV Technologies’s reported figures.

Based on trailing twelve months.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's earnings yield?
DBV Technologies (DBVT) reported earnings yield of -14.4% in Q1 2026.
How has DBV Technologies's earnings yield changed year-over-year?
DBV Technologies's earnings yield increased by 82.3% year-over-year, from -81.2% to -14.4%.
What is the long-term trend for DBV Technologies's earnings yield?
Over 5 years (2020 to 2025), DBV Technologies's earnings yield has grown at a -19.2% compound annual growth rate (CAGR), from -55.4% to -19.1%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.